He is forty-five and did everything asked of him: medications reviewed, the acid blocker gone, sleep protected, fiber back on the plate, bile moving again. Five months later he was about sixty percent better and going no further.
Most advice on how to heal leaky gut would have handed him another bottle and more patience. His urine said something more specific. His lactulose-to-mannitol ratio still sat above range, so the wall itself had not closed, even though every upstream cause had been addressed.
I’m Dr. Gurpreet Singh Padda, MD, MBA, MHP. The Chapter 29 video of The Angry Gut, A Plateau Is Not a Personality, covers the materials a barrier needs. Here the focus is measurement and repair: which test reads the wall, which nutrients have human data behind them, which rest on chemistry, and how to know on a set date whether any of it worked.
How to heal leaky gut: start with a test that can actually see the wall
He arrived with a zonulin result. The commercial kits were built from the first published sequence for zonulin, which was later shown to be unrelated to the protein. When a German team captured what the kit’s antibody binds in serum from 376 people, none of those proteins was the one the kit is named for. Three separate validation teams, 133 people between them, found no meaningful link between the kit and measured permeability. The scientist who first described zonulin signed the correction. The full story is in why the zonulin test cannot see your gut wall.
The replacement is older and less glamorous. You drink two sugars. Mannitol is small and passes through the lining cells, so it reports how much absorbing surface you have. Lactulose is larger and only crosses when the junctions between cells have loosened. Both appear in urine over about six hours. Dividing one by the other cancels out stomach emptying, how much you drank and kidney clearance, leaving a number that climbs when the gaps open.
Glutamine: why a pooled average and one trial disagree
A systematic review found 39 human studies of glutamine. Pooled, it moved the dual-sugar ratio by a mean difference of 0.01, statistically certain and clinically tiny. Those studies were largely in surgical and critically ill patients, where the pooled odds ratio for mortality of 0.48 is a hospital nutrition result, not an outpatient repair result.
Now the trial that ran hotter. It enrolled only adults with post-infectious, diarrhea-predominant IBS and a leak confirmed before treatment, and finished with 106 people. On 5 g three times daily for eight weeks, the ratio fell from 0.11 to 0.05, six times the pooled figure, and hyperpermeability came back into range in the treated group only.
Both results can be true. Enroll only people whose barrier is measurably open and you remove everyone with nothing to fix. It is one research group without independent replication, so the sugar test is repeated at the end of the course.
Zinc: read your plate before the label
A model built from national food supplies estimates 17.3% of the world’s population is at risk of inadequate zinc intake. Risk fell with total food energy and with the share of zinc from animal foods. It rose with the phytate-to-zinc ratio. Phytate is how grains and legumes store phosphorus, and it binds zinc in the gut before absorption.
The authors asked for direct measurement, not reasoning from the map. That is the practical step: check a zinc level. The plate matters as much as the pill. A diet built on inexpensive grain and bean staples carries its own zinc blocker.
If zinc carnosine is used, the dose matters. The human permeability study used 37.5 mg twice daily in ten volunteers. The 75 mg twice daily printed on most bottles came from stomach infection eradication trials that never measured a barrier.
Glycine and collagen: a supply argument, labeled as one
More than 85% of the body’s glycine is made from serine, and that pathway has a built-in ceiling. Roughly 3 g a day from synthesis plus 1.5 to 3.0 g from food leaves a 70 kg adult about 10 g a day short of demand, collagen synthesis included. That is a flux calculation from published rates, not a deficiency seen in a patient, and it says nothing direct about the bowel.
The popular delivery vehicle has a weaker record. A collagen peptide study recruited 40 people and 14 finished the course, 35%. The common 20 g daily dose came from what dietitians were already prescribing, not from a test against a barrier endpoint. How collagen fits the wall’s structure is in feeding the wall before you buy the powder.
Vitamin D to a level, and the drug that missed
In 27 people with Crohn’s disease in remission, 2,000 IU of vitamin D daily for three months held permeability steady, while in the placebo group small bowel and gastroduodenal permeability worsened. The paper did not report a significant difference between groups. The more useful finding is a threshold: people who reached a blood level of 75 nmol/L or higher had lower CRP and higher levels of the antimicrobial peptide LL-37. That is a post-hoc analysis, and it is the reason to dose to a level and recheck, as laid out in what your vitamin D blood test measures.
The one drug built to tighten intestinal junctions, larazotide acetate, tells the other half. Pooled across 4 randomized trials and 626 patients with celiac disease, the dual-sugar ratio did not separate from placebo, and symptoms improved only under gluten challenge. The sponsor ended phase 3 without publishing an efficacy result. One molecule missing its target says sealing junctions with a drug is hard. It does not say the target is imaginary, and it is why materials carry the weight.
Set the re-test date before the first dose
His plan was specific: zinc carnosine at the studied permeability dose, glutamine at the trial dose for eight weeks, glycine on the arithmetic, vitamin D to a blood level, and GABA aimed at his bowel as the thinnest item. The re-test date was set before any of it started.
That combination has never been trialed and will not be. Trials exclude metabolic disease, long medication lists and messy histories because clean cohorts are cheaper and faster to publish, so the evidence thins exactly where real patients cluster. Untested and ineffective are different claims.
His ratio came back inside range at twelve weeks, the first time in four years. That is one man, practice-reported figures from our own population, not trial outcomes, and individual results vary. The general version: audit the terrain, measure the wall, supply what it lacks at studied doses, and measure again on the date you chose. The previous post covered what TUDCA and milk thistle actually move, and why a healed gut has no discharge date comes next. Every study here, with full numbers and limits, is in the Chapter 29 Deep Dive.
Frequently asked questions
How long does it take to heal a leaky gut?
There is no universal clock, which is why the re-test date matters more than the promise. The strongest glutamine trial ran eight weeks and measured the ratio at the end. In our practice, one patient’s ratio returned to range at twelve weeks after four years open, a practice-reported result, and individual results vary. Pick a date before you start. How the gut drives joint pain shows what else can shift as the barrier improves.
What does a lactulose mannitol test measure?
It measures two things at once. Mannitol, a small sugar, crosses through lining cells and reflects absorbing surface. Lactulose, a larger sugar, crosses mainly when junctions between cells loosen. Both are collected in urine over hours, and their ratio cancels out stomach emptying, fluid volume and kidney clearance. A rising ratio signals a more open barrier. What inflammation biomarkers like hsCRP can tell you covers the blood side of the terrain.
Which foods block zinc absorption?
Foods high in phytate, mainly grains and legumes, bind zinc in the gut before it can be absorbed. In a global food-supply model, zinc deficiency risk rose with the phytate-to-zinc ratio and fell with the share of zinc from animal foods. That is not a reason to drop plants; it is a reason to check a zinc level. What your gut wall is built from covers the fats in the same membranes.
Is glutamine safe for gut repair?
In the trial of adults with post-infectious IBS and measured permeability, adverse events and discontinuation rates were low and similar to placebo, with no serious adverse events at 5 g three times daily for eight weeks. That speaks to that dose, duration and population. Anyone with kidney or liver disease should review it with a physician first. Why the same treatment helps one body and fails another explains why terrain matters.
Why did a drug made to seal the gut fail?
Larazotide acetate was designed to tighten intestinal junctions in celiac disease. Pooled across four trials, it did not improve the dual-sugar ratio compared with placebo, and symptom benefit appeared only in patients given gluten. Phase 3 was stopped without a published efficacy result. That shows drug-based sealing is difficult, not that the barrier is unimportant. What causes Crohn’s disease beyond genes covers how gut triggers and immunity interact.
Measure the wall before you treat it
If your gut progress has stalled after the obvious fixes, a Regen.MD evaluation starts with a real permeability measurement, the nutrient levels behind repair and a date to re-test.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Sources
- Scheffler, L., Crane, A., Heyne, H., Tönjes, A., Schleinitz, D., Ihling, C. H., Stumvoll, M., Freire, R., Fiorentino, M., Fasano, A., Kovacs, P., & Heiker, J. T. (2018). Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Frontiers in Endocrinology, 9, 22. https://doi.org/10.3389/fendo.2018.00022
- Massier, L., Chakaroun, R., Kovacs, P., & Heiker, J. T. (2021). Blurring the picture in leaky gut research: How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut, 70(9), 1801-1802. https://doi.org/10.1136/gutjnl-2020-323026
- Arribas-López, E., Zand, N., Ojo, O., Snowden, M. J., & Kochhar, T. (2021). The effect of amino acids on wound healing: A systematic review and meta-analysis on arginine and glutamine. Nutrients, 13(8), 2498. https://doi.org/10.3390/nu13082498
- Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N. (2019). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut, 68(6), 996-1002. https://doi.org/10.1136/gutjnl-2017-315136
- Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: Results based on zinc availability in national food supplies and the prevalence of stunting. PLoS One, 7(11), e50568. https://doi.org/10.1371/journal.pone.0050568
- Mahmood, A., FitzGerald, A. J., Marchbank, T., Ntatsaki, E., Murray, D., Ghosh, S., & Playford, R. J. (2006). Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut, 56(2), 168-175. https://doi.org/10.1136/gut.2006.099929
- Meléndez-Hevia, E., De Paz-Lugo, P., Cornish-Bowden, A., & Cárdenas, M. L. (2009). A weak link in metabolism: The metabolic capacity for glycine biosynthesis does not satisfy the need for collagen synthesis. Journal of Biosciences, 34(6), 853-872. https://doi.org/10.1007/s12038-009-0100-9
- Abrahams, M., O’Grady, R., & Prawitt, J. (2022). Effect of a daily collagen peptide supplement on digestive symptoms in healthy women: 2-phase mixed methods study. JMIR Formative Research, 6(5), e36339. https://doi.org/10.2196/36339
- Raftery, T., Martineau, A. R., Greiller, C. L., Ghosh, S., McNamara, D., Bennett, K., Meddings, J., & O’Sullivan, M. (2015). Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United European Gastroenterology Journal, 3(3), 294-302. https://doi.org/10.1177/2050640615572176
- Hoilat, G. J., Altowairqi, A. K., Ayas, M. F., Alhaddab, N. T., Alnujaidi, R. A., Alharbi, H. A., Alyahyawi, N., Kamal, A., Alhabeeb, H., Albazee, E., Almustanyir, S., & Abu-Zaid, A. (2022). Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 46(1), 101782. https://doi.org/10.1016/j.clinre.2021.101782